May 31

AuroSource – Custom Research and Manufacturing Division of Aurobindo Pharma

A unparalleled pharmaceutical manufacturing company, Aurobindo Pharma is headquartered at Hyderabad, India. The company which commenced operations with a single unit manufacturing Semi-Synthetic Penicillin (SSP), has now evolved into a knowledge driven company that manufacturing active pharmaceutical ingredients and formula products.

Aurobindo Pharma is R&D focused and has a multi-product portfolio with manufacturing facilities in several countries. They are ditto one from the few companies to be present across the beta-lactam and non-beta-lactam segments. The company is associated with UNO for development of ARVs, and contributes to excessive 2300 dossier filings worldwide.

The Custom Research ampersand Manufacturing division of Aurobindo Pharma, AuroSource offers the global bio-tech and pharmaceutical community a refreshingly new approach for outsourcing chemistry services with a dedicated focus on enhancing apprize with our customers. AuroSource offers project-based customer centricity in chemistry services.

Research at AuroSource is supported by a state-of-the-art R&D division located juxtapose Hyderabad. Amidst an experience of over 200 APIs commercialization the investigation team is completely attuned to our business needs.

AuroSource has vast expertise in developing and manufacturing customized APIs, intermediates, starting raw materials and stability study. They also offer solutions to manage the complete product lifecycle including extensions and regulatory support.

Along with this, AuroSource also has over 1000 regulatory filings, and exports to above 125 countries. The R&D division is hugely experienced in each types of chemistry.

Manufacturing Facilities
AuroSource offers flexibility with five API development and manufacturing facilities, accredited by international regulatory bodies such as USFDA, MHRA, Health Canada, TGA, ANVISA and SA MCC.

* In stability studies, AuroSource has effectively implemented global stability protocols for stability analysis.
* These facilities have shuffle in chambers for entireness ICH conditions with capacities of up to 100,000 litres. All stability chambers are continuously monitored.
* State-of-the-art manufacturing facilities that support aptitude in GMP connective non-GMP processes allowing AuroSource to extend a highly competitive side to its customers with API manufacturing needs.

Aurobindo Pharma’s manufacturing services cover the customer’s needs from R&D to plant scale material for clinical trials, and more specialized capabilities. We offer six modern scalable facilities with a total reaction volume in excess of 4500 cubic meters.

Global Expansion
AuroSource has a global presence across 100 countries including key players such as China, Brazil, Japan, Netherlands, South Africa, Thailand, UK, USA and Russia. In India, the parent company, Aurobindo Pharma has three dedicated research centres, making it one of the largest R&D facilities in the country.